A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder C

Administered By

Awarded By

Contributors

Start/End

  • January 30, 2017 - October 31, 2019